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1. Introduction
  Malaria remains one of the most important infectious 
diseases in the world.  It constitutes a public health 
problem in more than 90 countries inhabited by about 
40% of the world’s population. Statistics of the World 
Health Organization in 2012 showed an estimate of about 
274  million malaria cases annually with approximately 
1.1 million deaths, mostly in children under five years 
old[1]. Of the five species of human malarial parasites, 
Plasmodium falciparum (P. falciparum) is remarkable for its 
high case fatality rate and resistance developed to existing 
antimalarial drugs.  The emergence and spread of multidrug 
resistant P. falciparum continue to be a major public health 
problem in the management and control of malaria in 
several endemic countries. This situation was particularly 
threatening until the introduction of artemisinin-based 
combination therapies (ACTs)[2]. It is being debated whether 
P. falciparum has developed resistance to artesunate-
mefloquine combination, one of the most commonly used 
ACTs. The increase in fifty percent inhibitory concentration 
(IC50) and a delay in parasite clearance have been observed 
following treatment with this combination[3-5]. The observed 
delayed parasite clearance suggests that some parasites 
can survive the treatment for a longer period of time than 
expected, although they are eventually killed by the drugs. 
This raises the possibility of a unique survival mechanism 
different from a classical drug-resistance phenotype. New 
effective and affordable antimalarial drugs are therefore 
urgently needed.  Plants are important sources of medicines 
including antimalarial drugs as in the cases of quinine 
and artemisinins[6]. The aim of the study was to assess 
the antimalarial activity (in vitro and in vivo) and toxicity 
of the crude ethanolic extract of Garcinia mangostana
(G. mangostana) Linn. or mangosteen. This fruit pericarp 
has been used in traditional medicine in several Asian 
countries for several purposes including treatment of skin 
infections and wounds[7,8].
Objective: To investigate the antimalarial activity and toxicity of the crude ethanolic extract of 
its pericarp both in vitro and in vivo. Methods: The antimalarial activity of Garcinia mangostana
(G. mangostana) Linn. extract against 3D7 and K1 Plasmodium falciparum (P. falciparum) clone 
were assessed using SYBR green 栺-based assay. A 4-day suppressive test of Plasmodium berghei
(P. berghei) infected mouse was performed to investigate in vivo antimalarial activity. Results: 
The in vitro antimalarial activity was selective (SI > 5) and classified as weak and good to 
moderate activity against both 3D7 and K1 P. falciparum clones with median IC50 (range) values 
of 11.12 (10.94-11.29) and 7.54 (6.80-7.68) 毺g/mL, respectively. The extract was considered non-
toxic to mice. The maximum tolerated doses for acute and subacute toxicity in mice were 5 000 
and 2 000 mg/kg, respectively. Median (range) parasite density on day 4 of the negative control 
group (25% Tween-80), mice treated with 250, 500, 1 000, and 2 000 mg/kg body weight of the 
extract, and 10 mg/kg body weight of chloroquine for 14 d were 12.8 (12.2-13.7), 11.4 (9.49-13.8), 
11.6 (9.9-12.5), 11.7 (10.6-12.8), 10.9 (9.4-11.6) and 0 (0-0)% respectively. Parasite density on day 4 
in the control group treated with Tween-80 was higher than the groups treated with chloroquine 
and all dose levels of the extract. Conclusions: G. mangostana Linn. showed weak antimalarial 
activity of the extract both in vitro and in vivo could be due to limitation of absorption of the 
active compounds.
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2.  Materials and methods 
2.1. Plant materials and preparation of the crude ethanolic 
extract of G. mangostana Linn. 
  G. mangostana Linn. fruits were purchased from Talard-
Tai Market in Pathumthani Province of Thailand. The fruit 
was rinsed thoroughly with tap water to remove extraneous 
contaminants and the pericarp was cut into small pieces, 
dried at 45 曟 and ground into powder with pestle and 
mortar.  Extraction was carried out by macerating the 
powder plant materials (100 g) in a flask containing 500 mL
of 95% ethanol (at 25-30 曟) for 7 d.  The extraction solvent 
was separated, filtered (through Whatman no.1 filter 
paper) and evaporated under reduced pressure by rotary 
evaporation. The ethanolic extract yield of 400 g dried weight 
of mangosteen pericarp powder was 10.55% (w/w).
2.2. Determination of fingerprint of the crude ethanolic 
extract of G. mangostana Linn. 
  Fingerprint of the crude ethanolic extract of G. mangostana
Linn. pericarp was analyzed by HPLC using 毩- mangostin 
as a chemical marker[9]. The HPLC system consists of a 
solvent delivery system (Spectra System P4000 Quaternary 
Solvent Delivery/Controller: Thermo Fisher Scientific, 
California, USA), equipped with solvent degasser 
(SpectraSystem SCM1000 Solvent Degasser: Thermo Fisher 
Scientific, California, USA), an auto sampler (SpectraSystem 
AS3500: Thermo Fisher Scientific, California, USA), and a 
UV detector (SpectraSystem UV/Vis3000: Thermo Fisher 
Scientific, California, USA).  The optimal wave length was 
set at 254 nm. The separation was carried out on a reversed-
phase column (Thermo Hypersil Gold C18, 250 mm伊2.1 mm 
i.d., 5 毺m: Thermo Scientific, California, USA).  The elution 
solvent consisted of water (A) and acetonitrile (B) running at 
a flow rate of 1.0 mL/min.  Total running time was 37 min 
and the gradient mode was as follow: 55% B to 85% B for 
0-30 min, constant at 85% B for 5 min, 85% B to 55% B for 1 
min, and constant at 55% B for 4 min.  The chromatographic 
analysis was operated at 25 曟.  An aliquot of 20 毺L of 
sample or standard solution was injected into the column.
2.3. In vitro experiment
2.3.1. Parasite culture
  P. falciparum chloroquine-resistant K1 and chloroquine-
sensitive 3D7 clones were kindly provided by the Malaria 
Research Unit, Institute of Health Research, Chulalongkorn 
University, Thailand.  Both clones were maintained in 
continuous culture in O+ human erythrocytes suspended 
in RPMI 1640 (Gibco, California, USA) culture medium 
supplemented with 10% human B serum and 25 mM HEPES 
(at 37 曟 under a gas mixture of 5% CO2, 5% O2 and 90% N2) 
according to the standard method described by Trager 
and Jensen[10]. The level of parasitemia in the culture was 
maintained between 2 and 10%.  Synchronization of the 
parasite culture to ring stage P. falciparum was performed 
using 5% sorbitol[11].
2.3.2. Assessment of antimalarial activity in vitro
  Antimalarial activity of the crude ethanolic extract of
G. mangostana Linn. pericarp was investigated in vitro using 
SYBR Green I assay[12,13]. Highly synchronous ring stage 
parasite was used in each assay.  An aliquot of parasite 
inoculum (50 毺L) with 2% parasitemia and 1% hematocrit 
was added into each well of microtiter plate. The extract 
(dissolved in dimethyl sulfoxide or DMSO and diluted with 
RPMI 1640 to final concentration of 1%) was added to the 
malaria culture at eight final concentrations of 0.78, 1.56, 
3.13, 6.25, 12.5, 25, 50 and 100 g/mL. Chloroquine (3.89-
498.15 nM) and artesunate (0.39-50.0 nM) were used as 
standard antimalarial drugs. The experiment was repeated 
three times (triplicate each). IC50 value (drug concentration 
that inhibits the parasite growth by 50%) was used as an 
indicator of antimalarial activity and was determined from 
a log-dose response curve plotted using the CalcusynTM 
version 1.1 (BioSoft, Cambridge, UK).
2.3.3. In vitro assay for cytotoxic activity
  Normal human epithelial cell (HRE) was purchased from 
Promocell Co. Ltd. (Heidelberg, Germany) and cultured in 
renal epithelial cell growth medium 2 supplemented with 
SupplementPack (Promocell Co. Ltd., Heidelberg, Germany). 
The cell was incubated at 37 ℃ in 5% CO2 atmosphere with 
95% humidity and was seeded in a 96-well plate at a density 
of 104 cells/well in 100 毺L culture medium. Following 24 h 
incubation and attachment, cells were treated with varying 
concentrations of each plant extract. The concentration 
range of the extract used was 1.95-250.00 毺g/mL.  After 48 h
incubation, following washing and incubation with MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromidesolution, 20 毺L of 5 mg/mL] at 37 ℃ for 3 h, cells 
were lyzed with DMSO. The yellow MTT dye was reduced by 
succinic dehydrogenase in the mitochondria of viable cells 
to purple formazan crystals.  Absorbance was measured 
at 570 nm using a microplate reader (Varioskan, Thermo, 
USA). Experiments were repeated three times, triplicate for 
each experiment). The IC50 values were determined using 
CalcySyn™ software (BioSoft, Cambridge, UK). The selectivity 
index (SI) was calculated from the IC50 ratio of each extract 
obtained from HRE cell and K1 or 3D7 clone.
2.4. In vivo experiments
2.4.1. Animals
  Imprinting control region (ICR) mice (5-7 weeks of age, 
weighting 20-40 g) of both genders were used in the study. 
All were obtained from the National Laboratory Animal 
Centre, Thailand. Animal experiments were carried out in 
accordance with the OECD Guideline for Chemicals. The 
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animals were housed under standard conditions and fed with 
a stock diet and water ad labitum.  Approval of the study 
protocol was obtained from the Ethics Committee for Animal 
Research, Thammasat University, Thailand.
2.4.2. Toxicity tests
  The ethanolic extract of G. mangostana Linn. (pericarp) 
was weighted and resuspended with 25% Tween-80 to obtain 
the desired concentrations. ICR mice were fasting 2 h before 
feeding with the extract. Animals were divided into four 
groups of six (3 males and 3 females for each group).  For 
the acute toxicity test, mice in each group were fed with 
the extract at a single oral dose of 5 000 mg/kg body weight; 
control group received a single oral dose of 25% Tween-80 
(1 mL).  For the subacute toxicity test, mice in each group 
were fed with the extract at a daily oral dose of 2 000 mg/kg
body weight for 14 d; control group received a daily oral 
dose 1 mL of 25% Tween-80 for 14 d. General behavior of 
each mouse was observed continuously for 1 h after each 
dose, intermittently every 4 h, and thereafter over a period 
of 24 h[14]. Animals were observed for up to 14 d for the 
acute toxicity test and 28 d for the subacute toxicity test for 
any sign of toxicity (behavioral change related to central 
nervous, cardiovascular and gastrointestinal systems as well 
as complete blood count, liver and kidney function tests), 
body weight change and water and food consumption. At the 
end of the observational period, all animals were sacrificed 
under ether anesthesia and vital organs (heart, lung, liver, 
spleen and kidney) were removed from all animals for gross 
and histopathological examination.
2.4.3. Assessment of antimalarial activity of plumbagin in 
Plasmodium berghei (P. berghei)-infected mouse model 
(4-day suppressive test)
  The in vivo antimalarial activity of the ethanolic extract 
of G. mangostana Linn. was evaluated using a 4-day 
suppressive test in P. berghei-infected mouse model[15].
P. berghei (ANKA) strain used in the experiment was 
obtained from the National Center for Genetic Engineering 
and Biotechnology (BIOTEC), Thailand. The parasite had 
been maintained by serial blood passage in mice, and blood 
stage stored at -196 ℃ until use.  
  ICR mice were divided into six groups (3 males and 3 
females for each group).  The donor mice were infected with 
200 毺L of P. berghei parasite inoculum. The parasitized 
blood of each donor mouse was collected from the tail vein 
and diluted with 0.9% sodium chloride.  Mice were infected 
with saline suspension of 1伊107 parasitized erythrocytes
(0.2 mL) by intraperitoneal injection (Day 0).  Four hours after 
infection, animals were treated with the ethanolic extract of 
G. mangostana Linn. at oral daily doses of 250, 500, 1 000 
or 2 000 mg/kg body weight for four consecutive days (test 
group 1, 2, 3 and 4, respectively).  Positive and negative 
control groups were fed with the antimalarial chloroquine at 
oral daily doses of 10 mg/kg body weight and 25% Tween-80, 
respectively.  On day 4 (96 h post infection), parasitemia of 
individual mouse was determined under light microscope by 
examination of giemsa-stained thin blood smears prepared 
from mouse tail blood[16].  The mean parasitemia in each 
group of mice was used to calculate the % suppression for 
each dose using the formula: 
Parasitemia of negative control - Parasitemia of test
Parasitemia of negative control
  The antimalarial activity of the ethanolic extract of 
G. mangostana Linn. was determined from the ratio of 
percentage of parasite reduction in treated and negative 
control groups[17]. Results are expressed as median (range) 
values. Comparison of difference in quantitative variables 
between more than two and two groups was performed using 
Kruskal Wallis and Mann-Whitney U tests (SPSS version 
12.0, SPSS Inc., California, USA). Statistical significance level 
was set at 毩<0.05 for all tests.
3. Results
3.1. In vitro antimalarial activities of G. mangostana Linn.
  The antimalarial activity of the ethanolic extract of
G. mangostana Linn. against 3D7 chloroquine-sensitive 
and K1 chloroquine-resistant P. falciparum clones were 
categorized as weak and good to moderate with median 
IC50 (range) values of 11.12 (10.94-11.29) and 7.54 (6.80-
7.68) g/mL, respectively. The corresponding IC50 values for 
chloroquine and artesunate were 10.5 vs. 128.7 and 2.1 vs 
1.91 nM, respectively. 
  Cytotoxicity assay was performed using normal human HRE 
cell line in order to evaluate the selectivity of antimalarial 
activity of the crude ethanolic extract of G. mangostana Linn. 
The median (range) IC50 value was 67.3 (58.00-71.60) 毺g/mL.
The antimalarial activity of the extract against both clones 
were found to be selective, with SI values of 6.04 and 8.90, 
respectively.
3.2. Toxicity tests
  The toxicity of the ethanolic extract of G. mangostana Linn. 
when given as a single oral dose (acute toxicity) and 14-
day daily doses (subacute toxicity) in mice was investigated 
in order to define optimal dose to be used for evaluation of 
its in vivo antimalarial activity in malarial mouse model. 
Results indicated virtually no toxicity of G. mangostana 
Linn. at a maximum single oral dose of 5 000 mg/kg body 
weight (acute toxicity, Figure 1) and daily oral doses of
2 000 mg/kg body weight for 14 d (subacute toxicity, Figure 
2). All mice survived and there was neither sign of toxicity 
nor significant change in water and food consumption 
and body weights of mice in both groups during the 14 d 
observation period. The gross examination of vital organs, 
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i.e., heart, lung, liver, spleen and kidney in both treated 
and control groups were similar either in size and cell 
morphology.
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Figure 1.  Median body weights of male and female mice (n=3 each) 
during the first 14 d following the administration of a single oral 
dose of 5 000 mg/kg body weight of the crude ethanolic extract of
G. mangostana Linn. pericarp compared with 25% Tween 80 (negative 
control) in acute toxicity test.
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Figure 2.  Median body weights of male and female mice (n=3 
each) during the first 14 d following the administration of daily oral 
doses of 2 000 mg/kg body weight of the crude ethanolic extract of 
G. mangostana Linn. pericarp for 28 d, compared with 25% Tween 80 
(negative control) in subacute toxicity test. 
3.3. Antimalarial activity of G. mangostana Linn. in
P. berghei-infected mouse model (4-day suppressive test) 
  Results of the 4-day suppressive antimalarial test of the 
ethanolic extract of G. mangostana Linn. and chloroquine in 
mice infected with P. berghei ANKA strain are summarized 
in Table 1. Median (range) parasite density on day 4 of the 
negative control group (25% Tween-80), mice treated with 
250, 500, 1 000 and 2 000 mg/kg body weight of the extract, 
and 10 mg/kg body weight of chloroquine for 14 d were 
12.8 (12.2-13.7), 11.4 (9.49-13.8), 11.6 (9.9-12.5), 11.7 (10.6-
12.8), 10.9 (9.4-11.6) and 0 (0-0)% respectively.  Parasite 
density on day 4 in the control group treated with Tween-
80 was higher than the groups treated with chloroquine and 
all dose levels of the extract. Chloroquine exhibited the 
most potent antimalarial activity with respect to its activity 
on reduction of parasitemia on day 4 and prolongation 
of survival time. Parasite density (%) on day 4 following 
chloroquine treatment (0%) was significantly lower than 25% 
Tween 80 (negative control) and the extract at all dose levels. 
In addition, parasite suppression (%) on day 4 of mice treated 
with chloroquine (100%) was significantly higher than the 
negative control group (0%) and the groups treated with the 
extract at the doses of 2 000 (14.4%), 1 000 (8.5%), 500 (9.3%) 
and 250 (10.5%) mg/kg body weight. The survival time in 
the group treated with chloroquine was also significantly 
shorter than the negative control and the groups treated with 
the extract at all dose levels. Parasitemia of mice treated 
with chloroquine started to rise on day 5 (0.20%) until day 8 
(24.11%) of treatment, while that was rising between 19%-
29% in mice treated with the extract (Table 2).
4. Discussion
  The in vitro antimalarial activity against K1 and 3D7 
P. falciparum clones of the crude ethanolic extract of
G. mangostana Linn. pericarp was categorized into good 
to moderate and weak to antimalarial acivities with 
median IC50 values of 7.54, and 11.12 毺g/mL, respectively. 
These findings were in agreement with that reported by 
Thiengsusuk and colleagues, where the IC50 of the extract 
against K1 and 3D7 P. falciparum clones were reported as 
Table 1
In vivo antimalarial activities of the ethanolic extract of G. mangostana Linn. pericarp against P. berghei ANKA strain.
Treatment Dose (mg/kg)
Median (range: %) of parasite 
density on Day 4
% Inhibition/ Suppression on
Day 4
Median (range: days) of survival 
time
25% Tween 80 -     12.8 (12.2-13.7)a   0.0     17 (15-18)d
G. mangostana Linn. 2 000  10.9 (9.4-11.6) 14.4 15 (9-17)
G. mangostana Linn. 1 000    11.7 (10.6-12.8)   8.5   16 (10-17) 
G. mangostana Linn.    500 11.6 (9.9-12.5)   9.3  16 (9-20)
G. mangostana Linn.    250    11.4 (9.49-13.8) 10.5  15 (8-17)
Chloroquine      10 0.0b 100.0c    10 (10-12) 
Data are presented as median (range), n = 6. aSignificantly higher than mice treated with 2 000, 1 000, 500, and 250  mg/kg of the extract 
(P<0.05);  bSignificantly lower than negative control (25% Tween 80), and mice treated with 2 000, 1 000, 500 and 250 mg/kg body weight of the 
extract (P=0.002);  cSignificantly higher than  mice treated with 2 000, 1 000, 500, and 250 mg/kg body weight of the extract (P=0.02);
d Significantly higher than  mice treated with 2 000 (P=0.029), 1 000 (P=0.037), 500 (P=0.030), and 250  (P= 0.031) mg/kg body weight of the 
extract, and  mice treated with  10 mg/kg body weight chloroquine (P=0.002).
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3.6 and 11.8 毺g/mL, respectively[18]. G. mangostana Linn. 
pericarp has been shown to contain phenolic compounds 
such as condensed tannins, anthocyanins and xanthone 
derivatives[19-21]. Over 68 xanthone-type compounds have 
been isolated including the major constituent 毩-mangostin, 
as well as 毬-mangostin, 毭-mangostin, garcinone E, 
gartanin and 9 hydroxycalabaxanthone[22]. Among them, 
毩-mangostin appears to be the most potent compound 
against both chlrooquine-resistant and chloroquine-
sensitive P. falciparum clones with IC50 ranging from 
3.7 to 20 毺M[23]. Both 毩-mangostin and 毬-mangostin 
were shown to exert inhibitory effects on the growth of D6
P. falciparum clone (chloroquine-sensitive) with mean IC50 
of 5.1 and 7.0 毺M, respectively[24]. A series of oxygenated 
xanthones was synthesized and their antimalarial activities 
were evaluated using a 4-day suppressive assay against 
ANKA P. berghei stain in BALB/c mice at repeated doses 
of 20 mg/kg body weight/d. The most active compound 
was 1, 3, 6, 8-tetrahydroxyxanthone, which reduced the 
percentage of erythrocytes infected by 70.5%, followed by 
norlichexanthone (44.3%) and its isomer 1,3,8-trihydroxy-
6-methylxanthone (37.0%). Di-C-allyl-dihydroxyxanthone 
showed notable activity but relatively weaker (33.4%) and 
1,3-dihydroxyxanthone exhibited very weak activity (15.1%)[25].
  Result of the in vivo antimalarial activity based on the 
standard 4-day suppressive test shown in the present 
study was also in accordance with the in vitro test showing 
moderate antimalarial activity of the ethanolic extract 
at the minimum dose of 250 mg/kg body weight/day. 
The mechanism of inhibition of P. falciparum growth by 
mangostin and derivatives is still unclear. However, it 
has been suggested that hydroxyxanthones exert their 
antiplasmodium activity through formation of soluble 
complexes with heme and thereby inhibiting parasite 
hemozoin formation, a process by which the malaria parasite 
protects itself against toxic effects of heme released following 
digestion of hemoglobin[24,26]. The extract was well tolerated 
when given to mice either at a single or repeated doses of up 
to 5 000 and 2 000 mg/kg body weight, respectively. Jujan and 
colleagues also reported no toxic effect of this plant in rats 
following a single oral dose of 5 000 mg/kg body weight[27]. 
In addition, a 28-day oral toxicity test at the dose of 1 000 
mg/kg body weight/day did not produce any significant 
dose-related changes on hematological parameters, serum 
biochemistry or histopathology of liver, kidney, lung, heart, 
spleen, adrenal grand, thymus, stomach and duodenum, 
small intestine, ovary, uterus, testis, epididymis muscle and 
nerve, thoracic spine eye, and brain[27]. In other studies, the 
crude extract (200 mg/kg body weight) and 毩-Mangostin 
were shown to increase serum glutamic oxaloacetic and 
serum glutamic pyruvic transaminase in mice and rats[28].  
  It was noted however that the survival time of mice treated 
with the extract at all dose levels including chloroquine 
observed in the present study were significantly shorter 
than the negative control. For chloroquine, this observation 
could be due to an increase in malaria disease severity as 
a consequence of rapid rise of parasitemia after day 5. It is 
possible that the antimalarial activity of the crude ethanolic 
extract of G. mangostana Linn. could be compromised by 
other inactive components. Furthermore, permeability of 
the active ingredients-and 毬-mangostin across intestinal 
membrane (Caco-2 cell) was shown to be extremely low 
(unpublished observation) and the oral bioavailability of 
毩-mangostin was also reported to be markedly low in 
rats[29]. Evidence of extensive first-pass metabolism of 毩
-mangostin[30] was provided in rats with an initial low 
plasma concentration followed by a rapid drop following 
oral dose administration.  This pharmacokinetic factor 
would have led to an inadequate plasma concentration 
of this active moiety to suppress the parasite. Chemical 
derivatization of -and/or 毬-mangostin, or preparation 
of modified formulation such as liposomal formulation is 
required to improve their systemic bioavailability. 
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Table 2
In vivo antimalarial activity (represented by % parasite density on Day 5, 6 and 8) of the crude ethanolic extract of G. mangostana Linn. pericarp 
against ANKA strain P. berghei.  
Treatment Dose (mg/kg)
Parasite density (%)
Day 5 Day 6 Day 8
25% Tween 80 - 21.44 18.40 20.62
G. mangostana Linn. 2 000 27.27 23.68 20.33
G. mangostana Linn. 1 000 28.76 26.21 21.50
G. mangostana Linn.    500 21.81 21.86 20.51
G. mangostana Linn.    250 23.04 28.28 19.25
Chloroquine     10   0.20   0.67 24.11
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